Technical Data
C7904-79B
COX 1 (Cyclooxygenase-1, PGHS-1, Prostaglandin Endoperoxide Synthase-1, PHS 1, Ovarian Cancer Marker)
Description:
The prostanoid family includes PGD2, PGE2, PGF2alpha, PGI2, thromboxane A2 and prostaglandins. The prostaglandins (PGs) are implicated in various physiological and pathophysiological events, including male fertility, menstruation, ovulation, pregnancy, implantation and inflamatory and neoplastic diseases. The biosynthesis of PGs and some other prostanoids is catalyzed in a rate limiting step by PG-H synthase (also known as cyclooxygenase (COX), PG-endoperoxidase synthase (PTGS)) which converts arachiodonic acid to prostaglandin/prostanoid precursor PGH2. Two cyclooxygenase isozymes, COX1 (human, 576aa, 69-72kD; chromosome 9) and COX2 (human, 604aa, 74kD; chromosome 1) have been identified. COX1 is a constitutively expressed isoform. it produces physiologically relevant prostanoids such as those in stomach and platelets. COX2 isoform is inducible. it is rapidly upregulated at inflamation sites. It forms proinflamatory prostanoids. The overexpression of COX2 also leads to tumerogenesis. Recently, a third isoform COX3 (canine 633aa; ~65kD in human aorta) has been reported. Two smaller COX1-derived proteins (partial COX1) PCOX1a (canine 414aa, ~53kD in human aorta) and PCOX1b have also been characterized. The COX3, but not PCOX1a, possesses glycosylation dependent cyclooxygenase activity. The nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the formation of prostaglandins by inhibiting the activity of cyclooxygenases (COX1, COX2 and COX3). This ability was associated with inhibition of COX, which converts arachidonic acid to the prostaglandin precursor prostaglandin H2.

COX1 may play an important role in regulating or promoting cell proliferation in some nromal and nepotistic cells. it catalyzes arachidonate + AH2 + 2 O2 = Prostaglandin H2 + A + H2O. This enzyme acts both as a dioxygenase and as a peroxidase. It acts as the first step in the formation of prostaglandins and thromboxanes. COX1 contains 1 EFG-like domain. It consists of 70kD subunits which are constitutively expressed. These subunits are involved in a range of physiological functions. Inhibition of gastric expressed COX1 resulted in most of the unwanted side effects. Non-steroidal inflammatory drugs (NSAIDs) treated the symptoms.

Applications:
Suitable for use in ELISA, Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1:100-1:500 (ECL). Detects ~70kD band in uninduced NIH/3T3 and other cells (2).
ELISA: 0.1-1ug/ml.
Optimal dilutions to be determined by the researcher.

Recommended Control Protein:
C7904-70: COX 1 (Cyclooxygenase-1, PGHS-1, Prostaglandin Endoperoxide Synthase-1, PHS 1, Ovarian Cancer Marker), Western Blot Control

Source: Ascites

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG2b4k2Affinity Purified
SizeStorageShippingSourceHost
100ul-20CBlue IceSheepMouse
Concentration:
As reported
Immunogen:
Highly purified ovine COX1 protein.
Purity:
Purified by Protein A/G affinity chromatography.
Form
Supplied as a lyophilized powder from PBS, 0.05% sodium azide.
Specificity:
Recognizes human COX1. No significant crossreactivity with COX2. Species Crossreactivity: Mouse, rat, human, and sheep.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. DeWitt, D.L., et al., J. Biol. Chem. 265: 5192-5198 (1990). 2. Diaz, A., et al., J. Biol. Chem. 267: 10816 (1992). 3. Morham, S.G., et al., Cell 83: 473-482 (1995). 4. Langerbach, R., et al., Cell 83: 483-492 (1995). 5. Tsuji, M., et al., Cell 83: 493-501 (1995). 6. O'Neil, P.O., et al., FEBS Lett. 330: 156-160 (1993).